Review of ongoing clinical trials in non-small-cell lung cancer: A status report for 2012 from the ClinicalTrials.gov web site

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 860-865

  Subramanian, Janakiraman ^a   Regenbogen, Thomas ^b   Nagaraj, Gayathri ^c   Lane, Alex ^b   Devarakonda, Siddhartha ^d   Zhou, Gongfu ^b   Govindan, Ramaswamy ^b,e  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d St Lukes Hospital   (United States)

^e Washington University in St Louis School of Medicine   (United States)

Author keywords

ClinicalTrials.gov; Lung cancer; Non small cell lung cancer; Ongoing studies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

CHINA; GENE TARGETING; HISTOLOGY; HUMAN; INDUSTRY; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UNITED STATES; UNIVERSITY;

EID: 84880921448     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318287c562     Document Type: Review

References (16)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-216.
3. Adams CP, Brantner VV. Spending on new drug development1. Health Econ 2010;19:130-141.
4. Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website. J Thorac Oncol 2010;5:1116-1119.
5. ClinicalTrials.gov Web site. Accessed 27 October, 2012. http://www. clinicaltrials.gov/ct2/about-site/background.
6. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823.
7. International committee of medical journal editors, website. Requirement of trial registration. Accessed 27 October, 2012. http://www.icmje.org/ publishing-10register.html.
8. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-5563.
9. Chan JK, Ueda SM, Sugiyama VE, et al. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol 2008;26:1511-1518.
10. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005;23:6982-6991.
11. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379-1391.
12. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-5993.
13. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15:406-420.
14. Schroen AT, Petroni GR, Wang H, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res 2012;18:256-262.
15. Baggstrom MQ, Waqar SN, Sezhiyan AK, et al. Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol 2011;6:98-102.
16. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-2726.